J&J's ketamine-based nasal spray Spravato approved by US FDA to treat depression
nasal spray Spravato to treat adults with major depressive disorder, the company said on Tuesday.
Budget with ET
Sitharaman has one job to do and it’s the most crucial one yet
Will Modi govt have something special for Nitish Kumar’s Bihar?
Budget should help in safeguarding India’s trade interests as Trump returns
The approval paves the way for use of Spravato in patients whose disease has stopped responding to at least two oral anti-depressants.
«Treatment-resistant depression can be very complicated, especially for patients who do not respond to oral antidepressants or cannot tolerate them,» said J&J's Bill Martin, who leads the company's neuroscience therapy development.
MDD is one of the most common psychiatric disorders, with an estimated 21 million adults in the U.S. living with the disease, according to J&J's estimates.
(You can now subscribe to our Economic Times WhatsApp channel)
Read more on economictimes.indiatimes.com
